ReNeuron Group plc ReNeuron wins Breakthrough of the Year Award
June 14 2019 - 5:09AM
RNS Non-Regulatory
TIDMRENE
ReNeuron Group plc
14 June 2019
14 June 2019 AIM: RENE
RNS Reach
ReNeuron Group plc
("ReNeuron" or the "Company")
ReNeuron wins Breakthrough of the Year Award
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, is delighted to announce
that it has won the 'Breakthrough of the Year' award at last
night's 2019 European Mediscience Awards in London.
This award underlines the strong clinical development and
commercial progress ReNeuron has made over the past year. This
includes positive data from the ongoing Phase 1/2a clinical trial
in Retinitis Pigmentosa and the signing of an exclusive licence
agreement with Shanghai Fosun Pharmaceutical Industrial Development
Co., Ltd. for the development, manufacture and commercialisation of
ReNeuron's CTX and hRPC cell therapy programmes in the People's
Republic of China.
Olav Hellebø, Chief Executive Officer of ReNeuron,
commented:
"We are delighted to have been awarded the Breakthrough of the
Year award at the 2019 European Mediscience Awards. We are greatly
encouraged by the progress we have made with our cell therapy
clinical development programmes for retinitis pigmentosa and stroke
disability over the past year and look forward to continuing to
advance our clinical and business development activities in the
months ahead."
The European Mediscience Awards is one of the largest annual
gathering of private and publicly quoted healthcare, biotech and
life sciences companies in Europe. It celebrates the best in the
sector and highlights the achievements of individuals and companies
operating within it.
ENDS
Contacts:
ReNeuron +44 (0) 20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (UK Media/Investor Relations) +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Argot Partners (US Media/Investor Relations)
Stephanie Marks, Claudia Styslinger +1 212 600 1902
Stifel Nicolaus Europe Limited (NOMAD and
Joint Broker)
Jonathan Senior, Stewart Wallace, Ben Maddison +44 (0) 20 7710 7600
N+1 Singer (Joint Broker)
Aubrey Powell, Mark Taylor +44 (0) 20 7496 3000
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop
'off-the-shelf' stem cell treatments, without the need for
immunosuppressive drugs. The Company's lead clinical-stage
candidates are in development for the blindness-causing disease,
retinitis pigmentosa and for disability as a result of stroke.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that would
otherwise be unable to reach their site of action. ReNeuron's
shares are traded on the London AIM market under the symbol RENE.L.
Further information on ReNeuron and its products can be found at
www.reneuron.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRACKQDKKBKDOAD
(END) Dow Jones Newswires
June 14, 2019 06:09 ET (10:09 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024